Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentre Phase IV Single Arm Clinical Trial to Evaluate the Safety and Efficacy of a Fixed Ratio Combination of Insulin Glargine and Lixisenatide in Adult Patients With Type 2 Diabetes Who Are Sub Optimally Controlled on Oral Anti-hyperglycemic Drugs and/or Basal Insulin/GLP-1 RA

NCT06716424 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06716424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06716424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentre Phase IV Single Arm Clinical Trial to Evaluate the Safety and Efficacy of a Fixed Ratio Combination of Insulin Glargine and Lixisenatide in Adult Patients With Type 2 Diabetes Who Are Sub Optimally Controlled on Oral Anti-hyperglycemic Drugs and/or Basal Insulin/GLP-1 RA
Lead sponsor
Sanofi
Phase
Phase 4
Overall status
Completed
Start date
January 6, 2025
Completion date
June 12, 2026
Enrollment
105 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes